Evaluation of the effect of the combination of the natural products Glizigen® and Oncoxin®-Viusid® in the treatment of high-grade cervical intraepithelial lesions . Phase II

aboratorios Catalysis S.L.0 个研究点目标入组 62 人开始时间: 2018年5月9日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment

•1. Patients that meet the diagnostic criteria.
•2. Patients with age =18 years.
•3. Patients with residual lesion greater than 3 mm after the initial punch, measurable by video colposcopy and with major changes (Criteria from Rio 2011).
•4. Patients that have a positive test to the oncogenic virus of the human papilloma (16, 18, 31, 33, 45, 52 and 58).
•5. Patients who give their informed consent to participation in writing.
•6. Patients who consent to perform the conization according to the study schedule.
•7. Patients with normal laboratory parameters within the limits established in the institution (complete blood count, platelets and erythrosedimentation

•1. Patients who have received surgical, ablative, radiant, immunomodulatory or chemotherapy treatment 30 days before recruitment.
•2. Patients pregnant or breastfeeding.
•3. Patients with acute cervico-vaginal infections.
•4. Patients with positive serology known to HIV and/or syphilis.
•5. Patients with diseases that compromise the state of consciousness or their possibility of collaboration.
•6. Patients with a history of severe allergic history.
•7. Patients who are participating in another research.

发起方

aboratorios Catalysis S.L.